Fertility and blood progesterone levels following LHRH-induced superovulation in FSH-treated anestrous goats.

Twenty mature, mixed-breed, seasonally anestrous female goats were used to study the effects of luteinizing hormone releasing hormone (LHRH) on ovulation rate, fertility, and blood progesterone levels following norgestomet-induced estrus and follicle stimulating hormone (FSH) treatments. Each goat received 6 mg norgestomet by subcutaneous (sc) implant and 3 mg intramuscularly, along with an intramuscular (im) injection of 5 mg estradiol valerate. Four injections of FSH were given for 2 d in divided doses of 10, 10, 5 and 5 mg im every 12 h, starting at 24 h before implant removal. The goats were randomly assigned to 1 of 2 equal treatment groups, and were treated with 2 intravenous (iv) injections of either 0.9% saline (control) or 300 ug LHRH at 24 and 48 h after the removal of the implants. All the goats exhibited estrus within 24 or 36 h of implant withdrawal and were mated to bucks of proven fertility. At laparotomy on Day 7 or 8 after the removal of the implants, the mean number of unovulated follicles was higher (P<0.05) in Group I than in Group II. The mean number of corpora lutea (ovulation rate), the total number of embryos and the number of normal embryos recovered were higher (P<0.05) in LHRH-treated does than in the controls. Treatment with LHRH resulted in 72.14% fertility (mean number of CL = 14) as compared with the controls with 64.29% fertility (mean number of CL = 2.8). The embryos obtained from goats in Group II were of more uniform developmental age regardless of the day of embryo collection, as compared with those of the controls. Plasma progesterone levels were significantly increased on Days 4 to 6 in both treatment groups. The results of this study have demonstrated that the FSH and LHRH treatment regimen increased follicular development, ovulation rate and blood progesterone levels in norgestomet-treated anestrous goats. Moreover, LHRH treatment enhanced fertility, and improved embryo quality as indicated by the significantly higher total number of embryos as well as the higher (P<0.05) number of normal recoverable embryos.

Regulation of in vitro progesterone release from caprine luteal tissues by prostaglandins E2 and F2a.

Luteal slices obtained from Day-10 cyclic, sexually mature, mixed-breed, superovulated goats were used to study the effects of prostaglandins E(2) and F(2)a (PGE(2) and PGF(2)a) on the release of progesterone. The goats were synchronized for estrus using a single intramuscular injection of 5 mg PGF(2)a given during the mid-luteal phase of the estrous cycle. Multiple follicular growth and superovulation were induced using a treatment regiment of follicle stimulating hormone (FSH) and luteinizing hormone releasing hormone (LHRH) previously standardized in our laboratory (1). The luteal slices were treated with PGE(2) or PGF(2)a at concentrations of 1 and 10 ng/ml each. Untreated luteal slices continued to release significant amounts of progesterone over the entire period of incubation (30 to 360 minutes). There was a progressive increase in progesterone accumulation following treatment with PGE(2) at both concentrations. The mean progesterone values were significantly higher in the PGE(2)-treated groups at all incubation periods than in the controls. Progesterone values at 10 ng/ml were higher (P<0.05) than at 1 ng/ml. Treatment with PGF(2)a decreased (P<0.05) progesterone release at 60 to 360 minutes of incubation compared with that of the corresponding controls for each incubation period. However, there appeared to be no differences (P>0.05) in mean progesterone values between the two concentrations of PGF(2)a. The results of this study showed that PGE(2) enhanced the release of progesterone by caprine luteal tissues, whereas PGF(2)a inhibited its release.

Prostaglandin E2 counteracts the effects of PGF2 alpha in indomethacin treated cycling gilts.

Twenty crossbred gilts with at least 2 consecutive estrous cycles of 18 to 21 days in length were used to study the effects of prostaglandins E2 and F2 alpha (PGE2 and PGF2 alpha) on luteal function in indomethacin (INDO) treated cycling gilts. Intrauterine and jugular vein catheters were surgically placed before day 7 of the treatment estrous cycle and gilts were randomly assigned to 1 of 5 treatment groups (4/group). With exception of the controls (Group I) all gilts received 3.3 mg/kg INDO every 8 h, Groups III, IV and V received 2.5 mg PGF2; 2.5 mg PGF2 alpha + 400 micrograms PGE2 every 4 hr, or 400 micrograms PGE2 every 4 h, respectively. All treatments were initiated on day 7 and continued until estrus or day 23. Jugular blood for progesterone analysis was collected twice daily from day 7 to 30. Estradiol-17 beta (E2-17 beta) concentrations were determined in samples collected twice daily, from 2 d before until 2 d following the day of estrus onset. When compared to pretreatment values, estrous cycle length was unaffected (P greater than 0.05) in Group I, prolonged (P less than 0.05) in Groups II, IV and V; and shortened (P less than 0.05) in Group III. The decline in plasma progesterone concentration that normally occurs around day 15 was unaffected (P greater than .05) in Group I; delayed (P less than 0.05) in Groups II, IV and V; and occurred early (P less than 0.05) in Group III. Mean E2-17 beta remained high (31.2 +/- 4.9 to 49.3 +/- 3.1 pg/ml) in Groups III and IV, while the mean concentrations in Groups III and V varied considerably (17.0 +/- 2.0 to 52.2 +/- 3.5 pg/ml). The results of this study have shown that PGE2 will counteract the effects of PGF2 alpha in INDO treated cycling gilts. The inclusion of PGF2 alpha appeared to either stimulate E2-17 beta secretion or maintain it at a higher level than other treatments.

Sparing effects of intrauterine treatment with prostaglandin E2 on luteal function in cycling gilts.

Twelve crossbred gilts, 8 to 9 months of age, were used to study the effects of prostaglandin E2 (PGE2) on luteal function during the estrous cycle. Intrauterine and jugular vein catheters were surgically placed before day 7 of the treatment estrous cycle and gilts were randomly assigned to 1 of 3 treatment groups. Groups I and II received constant intrauterine infusion of vehicle (6.0 ml/24 hr) or PGE2 (2400 micrograms/day; 6.0 ml/24 hr) respectively; while group III was given intrauterine infusions of 400 micrograms PGE2 every 4 hr. All infusions were initiated on day 7 and continued until estrus or through day 23. Jugular blood samples were collected twice daily from days 7 to 30 for progesterone analysis. Intrauterine infusion of PGE2 at the dose and frequencies given in this study delayed the decline in jugular plasma progesterone and resulted in prolongation of the estrous cycle length. The results of this study have shown that PGE2 at the dosage and frequency of administration used was capable of extending corpus luteum function.

Detection of ovulation in goats by blood prostaglandins concentrations.

Eighteen mature female goats of nondescript breed were randomly assigned equally to 3 treatment groups. Group I goats served as controls, group II goats were treated (IV) with a single dose of 300 micrograms of synthetic luteinizing hormone-releasing hormone (LHRH); group III goats were treated with LHRH (similar to group II) and 24 hours later were given indomethacin (10 mg/kg; IM) which dosing was repeated every 6 hours for the next 90 hours. Blood samples were collected from all animals every 6 hours until 120 hours and assayed for prostaglandin E (PGE) and PGF2 alpha. On days 7 and 8, the animals were surgically laparotomized to observe the ovarian activity. In groups I and III goats, there was no evidence of follicular development or ovulation, but in 4 of the 6 group II goats, there were ovulatory points or corpus luteum. Mean plasma PGE and PGF2 alpha concentrations in control goats did not vary significantly (P less than or equal to 0.05) during the sampling period; but in the LHRH-treated goats (group II), these concentrations peaked twice--a low peak at 24 hours and a sharp peak at 78 to 90 hours. In contrast, these concentrations in group III goats (LHRH plus indomethacin) dropped sharply in the control group (I) value after reaching the 1st peak, and then stayed at this low plateau for the remainder of the sampling period; the 2nd peak was absent. The results indicate that the ovulation could be induced by LHRH injection in anestrus goats and that ovulation is preceded by a marked increase of plasma PGE and PGF2 alpha concentrations.